Neonatal SEPSIS Clinical Trial
— RAINOfficial title:
Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness
NCT number | NCT03247920 |
Other study ID # | RAIN |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | November 4, 2017 |
Est. completion date | July 15, 2021 |
Verified date | August 2021 |
Source | Franciscus Gasthuis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized controlled open-label non-inferiority trial comparing complete intravenous antibiotic treatment with a short iv. course followed by oral antibiotics in neonates (0-28 days) with probable bacterial infection. Primary outcome: - Bacterial re-infection within 28 days after finishing of antibacterial therapy. Secondary outcome(s): - Pharmacokinetic profile of oral amoxicillin/clavulanic acid - Quality of life - Cost-effectiveness - Alterations in gut microbiome - Use of molecular techniques for better detection of bacterial pathogens
Status | Completed |
Enrollment | 510 |
Est. completion date | July 15, 2021 |
Est. primary completion date | June 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 28 Days |
Eligibility | Inclusion Criteria: - Neonates (= 35+0 weeks, 0-28 days old, = 2 kg) - Probable bacterial infection defined as clinical symptoms and/or maternal risk factors and elevated inflammatory markers for which empiric broad-spectrum antibiotic treatment was initiated and needs to be continued for > 48 hours - Clinically well - Toleration of oral feeding without overt vomiting - Signed informed consent Exclusion Criteria: - Proven bloodstream infection - Absence of blood culture - Severe localized infection (meningitis, osteomyelitis, necrotizing enterocolitis) - Severe clinical sepsis (compromised circulation, need for mechanical ventilation) - Continuous need for a central venous line - Severe hyperbilirubinemia exceeding the exchange level - Parents inability to administer medication - Major congenital or syndromic anomalies |
Country | Name | City | State |
---|---|---|---|
Netherlands | Meander Medical Center | Amersfoort | |
Netherlands | Rijnstate Hospital | Arnhem | |
Netherlands | Amphia Hospital | Breda | |
Netherlands | IJsselland Ziekenhuis | Capelle Aan Den IJssel | |
Netherlands | Reinier de Graaf Gasthuis | Delft | |
Netherlands | Haaglanden Medical Center | Den Haag | |
Netherlands | Juliana Kinderziekenhuis-Haga Hospital | Den Haag | |
Netherlands | Catharina Hospital | Eindhoven | |
Netherlands | Medisch Spectrum Twente | Enschede | |
Netherlands | Groene Hart Ziekenhuis | Gouda | |
Netherlands | Sint Antonius Ziekenhuis | Nieuwegein | |
Netherlands | Erasmus MC-Sophia Children's Hospital | Rotterdam | |
Netherlands | Franciscus Gasthuis | Rotterdam | |
Netherlands | Ikazia Ziekenhuis | Rotterdam | |
Netherlands | Maasstad Hospital | Rotterdam | |
Netherlands | Franciscus Vlietland | Schiedam | |
Netherlands | Maxima Medisch Centrum | Veldhoven | |
Netherlands | Isala | Zwolle |
Lead Sponsor | Collaborator |
---|---|
Franciscus Gasthuis | Erasmus Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bacterial re-infection within 28 days after cessation of antibiotic treatment (within 35 days after initial presentation) | 0-35 days | ||
Secondary | Duration of hospitalization | 0-35 days after birth | ||
Secondary | Percentage of re-admission | 0-35 days after birth | ||
Secondary | Total costs and cost-effectiveness | Cost-effectiveness of intravenous to oral switch compared to a full course of antibiotics + possible extra costs due to early antibiotic switch | 0-35 days after birth | |
Secondary | Difference in Quality of Life between oral and intravenous antibiotic treatment | Two questionnaires on day 7 and 21 after admission, filled in by both parents. Data will be provided in a descriptive manner as no validated QoL questionnaires exist for neonates. | 0-35 days after birth | |
Secondary | Time above MIC (T>MIC) of oral amoxicillin. | 2 blood samples after administration of antibiotic suspension at different time points will be taken.
Time above MIC (T>MIC) will be defined. Target MIC is 8 mg/liter. |
0-7 days | |
Secondary | Time above MIC (T>MIC) of oral clavulanic acid. | 2 blood samples after administration of antibiotic suspension at different time points will be taken.
Time above MIC (T>MIC) will be defined. Target MIC is 8 mg/liter. |
0-7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05692128 -
Frequency and Severity of Thrombocytopenia in Neonatal Sepsis
|
||
Completed |
NCT00942084 -
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
|
Phase 1 | |
Completed |
NCT06002295 -
A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns
|
Phase 2 | |
Not yet recruiting |
NCT05114057 -
Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI
|
N/A | |
Recruiting |
NCT04528251 -
Comparison of the Effectiveness of Two Different Antibiotic Regimens of the Treatment of Pregnant Women With Preterm Rupture of Membranes
|
||
Active, not recruiting |
NCT03871491 -
Azithromycin-Prevention in Labor Use Study (A-PLUS)
|
Phase 3 | |
Completed |
NCT03746743 -
Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II
|
||
Completed |
NCT02386592 -
Prevention of Nosocomial Bacteremia Among Zambian Neonates
|
N/A | |
Not yet recruiting |
NCT06113653 -
Outcomes and Predictors of Mortality Among Preterm Infants With Neonatal Sepsis
|
||
Completed |
NCT03199547 -
Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death
|
Phase 3 | |
Completed |
NCT02147327 -
Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities
|
N/A | |
Completed |
NCT01005589 -
CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis
|
N/A | |
Completed |
NCT00866567 -
Defects in Opsonophagocytosis in Premature Infants
|
N/A | |
Completed |
NCT02281890 -
Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database
|
N/A | |
Suspended |
NCT05156333 -
Probiotics and GBS Colonization in Pregnancy
|
N/A | |
Recruiting |
NCT05127070 -
Evaluating the NeoTree in Malawi and Zimbabwe
|
||
Completed |
NCT03755635 -
Neonatal Sepsis at Neonatal Intensive Care Units in Ghana
|
N/A | |
Completed |
NCT03295162 -
Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis
|
Phase 1/Phase 2 | |
Completed |
NCT02954926 -
Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
|
Phase 3 | |
Withdrawn |
NCT01723501 -
Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing <1500 g at Birth
|
Phase 2/Phase 3 |